CLARIUS-MOBILE-HEALTH
Clarius Mobile Health, a global leader in wireless ultrasound solutions, has received CE Mark for its revolutionary Clarius PAL HD3 wireless handheld whole-body ultrasound scanner combining phased and linear arrays on a single head. It offers superior image quality of superficial and deep anatomy at the bedside1. The Clarius PAL HD3 high-definition wireless scanner is available today in Europe and the United Kingdom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240117813694/en/
New Clarius PAL HD3 wireless handheld whole-body ultrasound scanner uniquely combines phased and linear arrays on a single head. It offers superior image quality of superficial and deep anatomy at the bedside. CE-Certified, it's now available in Europe, the United Kingdom and the United States. (Graphic: Business Wire)
“You can probably do 95 to 99% of all the ultrasound imaging you need to do during a shift with this single device,” says Dr. Tom Cook who practices at a busy urban hospital. “If you compare the cost of this device to a cart-based system, you're talking a factor of 10 to 15, maybe even 20, depending on the type of system you're using. So, it's very, very inexpensive.”
Clarius is as compact as an iPhone and works seamlessly with iOS or Android devices, ensuring easy mobility from patient to patient. Clarius PAL HD3 is the only whole-body handheld scanner to deliver high-resolution images from the skin down to 40 cm of depth. Healthcare professionals can perform whole-body ultrasound exams without the need to swap devices or transport bulky systems between rooms. Clarius PAL HD3 is the 11th wireless handheld ultrasound scanner in the Clarius specialty ultrasound lineup.
“Our unique dual-array design was driven by our objective to deliver a portable whole-body ultrasound device that produces superior imaging quality, performance, and usability than what was currently available for clinicians,” says Kris Dickie, Chief Technology Officer at Clarius who led the project from ideation to commercialization. “Given the sales volume of the Clarius PAL since we introduced it in the United States late last year, we’re happy to confirm there’s definitely a strong market for a single, versatile device that supports multiple exams and broad clinical applications for hospital physicians.”
Clarius ultrasound scanners are proven to deliver superior image quality.1 Clarius uses the same advanced 8 beamformer processing technology used by higher-end traditional systems. This delivers up to 8 times the speed and performance of other handhelds for clear and detailed imaging to guide safe procedures and support precise and rapid assessments of patients at the bedside.
Watch this video to learn more about Clarius PAL HD3 from three emergency physicians.
1. Park KE, Mehta P, Tran C, Parikh AO, Zhou Q, Zhang-Nunes S. A comparison of five point-of-care ultrasound devices for use in ophthalmology and facial aesthetics. Ultrasound. 2023;0(0). doi:10.1177/1742271X231166895 |
About Clarius Mobile Health
Clarius is on a mission to make accurate, easy-to-use, and affordable ultrasound tools available to all medical professionals in every specialty. With decades of experience in medical imaging, the team knows that great ultrasound imaging improves confidence and patient care. Clarius handheld wireless ultrasound scanners connect to iOS and Android devices, delivering high-resolution ultrasound images traditionally only available with bulkier, high-end systems at a fraction of the cost.
Over four million high-definition scans have been performed using Clarius wireless handheld scanners. Clarius scanners are available in over 90 countries worldwide. Learn more at www.clarius.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240117813694/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Announces Industry First 5G-Advanced 3GPP R18 Automotive-Grade Cellular Module, Delivering Unmatched Performance and Reliability2.1.2026 18:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announces the launch of the world's first 5G-advanced (5G-A) automotive-grade cellular module, the AR588MA, establishing it as the industry's highest-performing and most reliable wireless communication product for vehicles. Based on MediaTek's latest-generation MT2739 platform, the AR588MA supports 5G-A communication technology and is the world's first to comply with the 3GPP R18 standard protocol. The module also features both NB-NTN and NR-NTN satellite communication capabilities, supports Dual SIM Dual Active (DSDA) technology, offering improved stability and reliability on cellular connections and includes intelligent driving scenario recognition. Designed in compliance with the AEC-Q104 Grade 2 automotive standard, it delivers faster, more stable connectivity and reliable security for in-vehicle communication and benefiting the on-roof applications like smart antenna for automotive with higher temperatu
Interactive Brokers’ Individual and Hedge Fund Clients Outperformed the S&P 500 on Average in 20252.1.2026 16:00:00 CET | Press release
Lower costs, global market access, and efficient execution contributed to stronger client outcomes. Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that its clients outperformed the S&P 500 Index in 2025, reflecting the benefits of cost efficiency, execution quality, and broad access to global markets. In 2025, Interactive Brokers’ individual clients achieved an average return of 19.20%, compared with the 17.9% return of the S&P 500 Index. During the same period, Interactive Brokers’ hedge fund clients achieved an average return of 28.91%, outperforming the index by approximately 11 percentage points. These results demonstrate how Interactive Brokers helps enhance client returns across the investment lifecycle. Global market access enables clients to allocate capital across various regions and asset classes, while lower trading and financing costs, along with efficient execution, help IBKR investors retain more of their returns over time. “Inv
Aeromexico Repeats as Most On-Time Global Airline; Qatar Airways Claims Platinum Award2.1.2026 11:00:00 CET | Press release
Virgin Atlantic wins new award as most improved airline for on-time performance Aeromexico maintained a 90.02% on-time performance to claim the world's most on-time global airline title for the second consecutive year, according to Cirium's 2025 On-Time Performance Review released today. The Mexican carrier becomes only the second airline to achieve consecutive global wins since Cirium launched the program in 2009, operating 188,859 flights across 23 countries while maintaining industry-leading schedule reliability. Aeromexico Holds Global Lead; Regional Champions Crowned Aeromexico secured the global airline title with 90.02% on-time performance, holding off strong competition from Saudia in second place with 86.53% and SAS with 86.09% in third. The margin between first and third place was 3.93 percentage points, reflecting the strong performance of Aeromexico in 2025. Regional winners included: North America: Delta Air Lines won for the fifth consecutive year with 80.90% on-time perf
Samsung Bioepis Begins Commercialization of BYOOVIZ®, Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 08:00:00 CET | Press release
Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ®BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI® (eculizumab), OBODENCE® (denosumab), and XBRYK® (denosumab)Pre-filled syringe (PFS) presentation to become available in Europe in the second quarter of 2026 Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizuma
Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 15:00:00 CET | Press release
The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
